Hopp til hovedinnhold

Statiner - kolesterolsenkende midler

Statiner reduserer produksjonen av LDL-kolesterol (den "farlige" typen), mens HDL-kolesterol (den "gode" typen) øker.

Sist revidert:


Hva er statiner?

Hvem har nytte av statiner?

Statiner hos eldre?

Hvem bør ikke bruke statiner?

Bivirkninger

Vil du vite mer?

Kilder

Referanser

Dette dokumentet er basert på det profesjonelle dokumentet C10 Lipidmodifiserende legemidler. Referanselisten for dette dokumentet vises nedenfor.

  1. Weng TC, Yang YH, Lin SJ, Tai SH. A systematic review and meta-analysis on the therapeutic equivalence of statins. J Clin Pharm Ther. 2010 Apr;35(2):139-51. PMID: 20456733. PubMed 
  2. Silverman MG, Ference BA, Im K,et al. Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions: A Systematic Review and Meta-analysis. JAMA. 2016 Sep 27;316(12):1289-97. PMID: 27673306. PubMed 
  3. Chopra V, Wesorick DH, Sussman JB, et al. Effect of perioperative statins on death, myocardial infarction, atrial fibrillation, and length of stay: A systematic review and meta-analysis. Arch Surg 2012; 147: 181-9. PubMed 
  4. Ying H, Wang J, Shen Z, Wang M, Zhou B. Impact of Lowering Low-Density Lipoprotein Cholesterol with Contemporary Lipid-Lowering Medicines on Cognitive Function: A Systematic Review and Meta-Analysis. Cardiovasc Drugs Ther. 2020 Aug 8. Epub ahead of print. PMID: 32770521. PubMed 
  5. Zhang X, Wen J, Zhang Z. Statins use and risk of dementia: A dose-response meta analysis. Medicine (Baltimore). 2018 Jul;97(30):e11304. PMID: 30045255.
  6. Abdelhamid AS, Brown TJ, Brainard JS, et al. Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2020;3(2):CD003177. Published 2020 Feb 29. doi:10.1002/14651858.CD003177.pub5 DOI 
  7. Lombardi M, Chiabrando JG, Vescovo GM, et al. Impact of Different Doses of Omega-3 Fatty Acids on Cardiovascular Outcomes: a Pairwise and Network Meta-analysis. Curr Atheroscler Rep. 2020 Jul 16;22(9):45. PMID: 32671519. PubMed 
  8. Hoang T, Kim J. Comparative Effect of Statins and Omega-3 Supplementation on Cardiovascular Events: Meta-Analysis and Network Meta-Analysis of 63 Randomized Controlled Trials Including 264,516 Participants. Nutrients. 2020 Jul 25;12(8):E2218. PMID: 32722395. PubMed 
  9. Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. N Engl J Med. 2015 Jun 18;372(25):2387-97. Epub 2015 Jun 3. PMID: 26039521. PubMed 
  10. Sabatine MS, Giugliano RP, Keech AC, et. al. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. N Engl J Med. 2017 May 4;376(18):1713-1722. Epub 2017 Mar 17. PMID: 28304224. PubMed 
  11. Zhou Z, Rahme E, Pilote L. Are statins created equal? Evidence from randomized trials of pravastatin, simvastatin, and atorvastatin for cardiovascular disease prevention. Am Heart J 2006; 151: 273-81. PubMed 
  12. Adams SP, Sekhon SS, Wright JM. Lipid-lowering efficacy of rosuvastatin. Cochrane Database of Systematic Reviews 2014, Issue 11. Art. No.: CD010254. Cochrane (DOI) 
  13. Howard JP, Wood FA, Finegold JA, et al. Side effect patterns in a crossover trial of statin, placebo, and no treatment. J Am Coll Cardiol 2021 Sep 21; 78:1210. PMID: 34531021 PubMed 
  14. Athyros VG, Tziomalos K, Gossios TD, et al. Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis. Lancet 2010; doi:10.1016/S0140-6736(10)61272-X. DOI 
  15. Tiniakou E. Statin-Associated Autoimmune Myopathy: Current Perspectives. Ther Clin Risk Manag. 2020 May 27;16:483-492. PMID: 32581543. PubMed 
  16. Mohaupt MG, Karas RH, Babiychuk EB, et al. Association between sratin-associated myopathy and skeletal muscle damage. CMAJ 2009; 181: E11-8. Canadian Medical Association Journal 
  17. Mansi I, et al. Statins and musculoskeletal conditions, arthropaties, and iinjuries. JAMA Intern Med 2013. doi:10.1001/jamainternmed.2013.6184 DOI 
  18. Dormuth CR, Hemmelgarn BR, Paterson JM, et al. Use of high potency statins and rates of admission for acute kidney injury: multicenter, retrospective observational analysis of administrative databases. BMJ 2013. doi:10.1136/bmj.f880 DOI 
  19. Navarese EP, Buffon A, Andreotti F, et al. Meta-Analysis of Impact of Different Types and Doses of Statins on New-Onset Diabetes Mellitus. Am J Cardiol 2013. doi:10.1016/j.amjcard.2012.12.037. DOI 
  20. Cederberg H, Stančáková A, Yaluri N, et al. Increased risk of diabetes with statin treatment is associated with impaired insulin sensitivity and insulin secretion: A 6 year follow-up study of the METSIM cohort. Diabetologia 2015 58:1109-17. PMID: 25754552 PubMed 
  21. Kusters DM, Lahsinoui HH, et al. Statin use during pregnancy: a systematic review and meta-analysis. Expert Rev Cardiovasc Ther 2012; 10: 363-78. PubMed 
  22. Bakkebø T. Lipidsenkende midler ved graviditet og amming. Utposten 2014; 3: 46-7. PubMed 
  23. Bateman BT, Hernandez-Diaz S, Fischer MA, et al. Statins and congenital malformations: cohort study. BMJ 2015; 350: h1035. doi:10.1136/bmj.h1035 DOI 

Referanser

  1. Sathasivam S, Lecky B. Statin induced myopathy. BMJ 2008; 337: a2286. BMJ (DOI)  
  2. Mohaupt MG, Kara RH, Babiychuk EB, et al. Association between statin-associated myopathy and skeletal muscle damage. CMAJ 2009; 181: E11-8. Canadian Medical Association Journal  
  3. Gillett RC, Norrell A. Considerations for safe use of statins: liver enzyme abnormalities and muscle toxicity. Am Fam Physician 2011; 83: 711-6. American Family Physician